Publication date: July 2017
Source:Biomedicine & Pharmacotherapy, Volume 91
Author(s): Zeynab Aliyari Serej, Abbas Ebrahimi Kalan, Ahmad Mehdipour, Hojjatollah Nozad Charoudeh
Dipeptidyl peptidase IV (DPPIV),11 Dipeptidyl peptidase IV (DPPIV) on the surface of certain cells, where it is also referred to as CD26, is involved in a vast majority of biological and pathological processes. CD26/DPPIV function contributes to cancer and tumor metastasis as well as inhibition of its expression which alters the expression of immune response-related genes. CD26/DPPIV is a widely distributed multifunctional integral membrane and secreted protein that is defined as early predictive biomarker in HIV, cancer and autoimmunity diseases like diabetes and multiple sclerosis. CD26/DPPIV-chemokine interaction may have a functional role in T-cells and overall immune function. It is expressed at low density on resting T cells, but is upregulated with T cell activation. In this review, we summarize valuable information about detailed biological aspects and pharmacokinetic characteristics of CD26/DPPIV and its clinical efficacy, focusing particularly on the role of CD26/DPPIV in immunological and non-immunological diseases. We also describe our recent work about umbilical cord blood (UCB)22 umbilical cord blood (UCB) hematopoietic stem cell transplantation strategies in which identified CD26+ cells can be differentiated to immune cells under certain culture condition.
http://ift.tt/2qQTZe1
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου